Layoffs hit J&J, Bristol Myers Squibb, Bayer (updated)
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline operations.
Why Did Bristol-Myers Squibb Co (BMY) Stock See 34.20% Surge in the Last 90 Days?
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at $52.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies. In premarket trading, shares were up 20% to $4.
Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which includes a $55M equity investment. Read more here.
Bristol-Myers wins FDA nod for Opdivo lung cancer indication
The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers Squibb's (NYSE:BMY) blockbuster immunotherapy ...
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
Law2d
Bristol-Myers Squibb Wins Dismissal of $6.4 Billion Lawsuit Alleging Intentional Delay of Cancer Drug
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel ...
Bristol Myers Beats $6.4 Billion Lawsuit Over Delayed Cancer Drug
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
Crain's New York5h
Big pharma companies layoff hundreds amid tepid sales and legal battles
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...